Somewhere between the third espresso and the fourth Slack message, a quiet experiment is unfolding in the tech world. Founders, VCs, and operators — people who would happily debate Series A term sheets at midnight — are dropping crumb-sized amounts of psilocybin into their morning routine and reporting back like amateur neuroscientists. Welcome to the so-called shroom boom, where ayahuasca, psychedelics, addiction recovery conversations, and the older idea of master plants are colliding with the productivity industrial complex.

It’s a strange moment. Magic mushrooms — the same fungi that defined a generation of 1960s counterculture — are now being microdosed before pitch meetings. Whether that’s a genuine evolution in human wellness or a tech-bro repackaging of an ancient sacrament depends on who you ask. So let’s actually ask.

What microdosing actually means (and what it doesn’t)

A microdose is small. Really small. Researchers like Dr. James Fadiman, who has spent decades documenting the practice, define it as roughly one-twentieth to one-tenth of a recreational dose — enough to nudge the nervous system, not enough to send you into the cosmos. You don’t hallucinate. You don’t see the walls breathe. Ideally, you barely notice anything other than feeling a touch more present.

People microdose all sorts of substances: psilocybin mushrooms, LSD, occasionally cannabis, and in rarer cases sub-perceptual amounts of DMT or even ayahuasca tinctures. Psilocybin is by far the most popular because it’s organic, relatively forgiving, and — at the moment — culturally fashionable. Protocols vary. Some follow Fadiman’s one-day-on, two-days-off cycle. Others do two days on, five off. A few people just take it when they feel like it, which researchers tend to politely call “not a protocol.”

And no, it’s not the same as sitting in a ceremony with a curandero and drinking a cup of brewed master plants for eight hours. A microdose is the opposite experience — quiet, undramatic, almost boring. That’s the point.

Why startup founders are reaching for psilocybin

The anecdotal case is consistent enough to be interesting. Founders describe sharper focus, less anxious chatter, a sense of being able to listen properly in conversations. One beverage entrepreneur in Florida told reporters that after he started microdosing, he found himself less reactive and more open — fewer doses of caffeine, fewer panicked spirals between meetings. A Los Angeles wellness founder calls her routine a “nano-dose,” about an eighth of a full dose, taken a few mornings a week. She says it dissolves anxiety the way a hot bath dissolves muscle tension.

A former Canadian finance consultant turned psychedelic educator put it most bluntly: microdosing, she says, let her get three days of work done in one. She’s now built a small business around teaching others to do the same.

You hear a few themes again and again from people who microdose seriously:

• Reduced background anxiety, especially the low-grade kind that disguises itself as “being busy.”
• A quieter relationship with the inner critic — less rumination, more action.
• Improved listening, which sounds soft until you notice how much modern work depends on it.
• A subtle shift in creativity, often described as ideas “connecting” rather than arriving in a flash.
• Better sleep on non-dose days, which surprises people.

That last one is interesting. Microdosers often say the effect compounds across the week, rather than living and dying inside the dose itself. Whether that’s real or a story they’re telling themselves is exactly where the science gets wobbly.

What the research actually shows about psychedelics and the brain

Here’s the honest version. Macro-dose psilocybin research — full ceremonial doses given in clinical settings — is genuinely promising. There are well-designed trials showing meaningful effects on treatment-resistant depression, end-of-life anxiety, and addiction recovery, particularly for alcohol and nicotine dependence. That body of work is one of the reasons psychedelics, addiction, and mental-health treatment now share so much real estate in medical journals.

Microdosing is a different story. The randomized, double-blind studies that do exist tend to show modest effects, much of which can be explained by expectation. As one Harvard-affiliated physician researcher has pointed out, almost everyone who microdoses believes it helps them, but the trials don’t cleanly confirm it. Creativity, focus, presence — these aren’t cholesterol levels. They’re slippery to measure. The gold-standard trial design doesn’t translate well to subjective wellness gains.

That doesn’t mean microdosing is fake. It means we’re early. The psychedelic research renaissance has had perhaps two decades of serious momentum, and most of that funding has gone toward the more dramatic, easier-to-measure clinical applications. Microdosing science is still catching up.

Is it legal, and what are the actual risks?

Under United States federal law, psilocybin is a Schedule I controlled substance. Possession is illegal. That’s the headline. The fine print is more interesting: Oregon allows supervised adult use through licensed service centers, Colorado has moved in a similar direction, and cities including Denver, San Francisco, Oakland, Seattle, and Minneapolis have decriminalized personal possession to varying degrees. Several state-level legalization efforts have stalled. Canada, meanwhile, is racing ahead with a patchwork of clinics, retreats, and brick-and-mortar mushroom shops operating in legal grey zones.

So legality depends entirely on where you’re standing when you swallow the capsule. None of this is legal advice — please do your own homework based on your jurisdiction.

As for safety, microdosing is generally considered lower-risk than full-dose use, but “lower risk” doesn’t mean “no risk.” A few honest caveats worth knowing:

1. People with a personal or family history of psychosis, schizophrenia, or bipolar disorder should be cautious. Psilocybin can destabilize those conditions, and microdosing is not exempt.
2. Psilocybin interacts with SSRIs, MAOIs, lithium, and various other psychiatric medications. Don’t combine without a knowledgeable clinician’s input.
3. There are some reports — limited but real — of cardiac valve concerns with very frequent long-term microdosing, because of the way these compounds bind to certain serotonin receptors.
4. Tolerance builds fast. Daily use is pointless within a week.
5. The supply is unregulated. Dose consistency from underground sources varies wildly.

Where retreats and master plants fit in

For a lot of people, microdosing isn’t the destination — it’s the doorway. Curious about psilocybin in small amounts, they eventually start reading about full-dose experiences, about ayahuasca, about the long-standing traditions of plant medicine and master plants in the Amazon and the Andes. That’s a meaningful step up in intensity, and it deserves a different kind of preparation.

If you’re weighing a retreat — psilocybin, ayahuasca, San Pedro, or something else in the plant-medicine family — a few things are worth thinking about before the credit card comes out. Who runs the retreat? What lineage or training do the facilitators come from? What’s the medical screening process? What does integration support look like in the weeks after you fly home? Is there a real container around the experience, or is it essentially a vacation with a substance attached?

The good retreats tend to ask you as many questions as you ask them. The questionable ones take your deposit before they’ve learned your last name. A retreat is not a productivity hack. It’s an experience that can reshape how you see your life, and the people guiding it matter enormously.

The cultural shift, and the people still hiding it

There’s a strange double life happening in tech right now. Some founders talk openly about their psilocybin practice on podcasts. Others won’t mention it out loud, even with VCs they suspect are doing the same thing. The 2021 firing of an Iterable CEO who admitted to dosing LSD before a meeting still hangs in the air as a cautionary tale.

That stigma is shifting, slowly. Investors are pouring money into psychedelic biotech. Cities and states are loosening laws. The conversation around psychedelics, addiction recovery, and mental health is moving from fringe to mainstream faster than almost anyone predicted ten years ago.

Still, the most thoughtful people in this world tend to caution against treating mushrooms as a life hack. The traditions that have used these plants for centuries don’t talk about productivity. They talk about humility, listening, and being changed by something larger than yourself. Worth holding both ideas at once.

If you’re curious, what now?

If you’ve read this far, you’re probably not looking for a hot take. You’re trying to figure out whether any of this is for you. A few honest suggestions:

• Get clear on what you actually want — focus, healing, curiosity, recovery from something specific. The answer shapes everything else.
• If you have a complicated mental-health history, talk to a clinician who actually understands psychedelics. They exist, and there are more every year.
• Read the research yourself. The peer-reviewed work on psilocybin for depression and addiction is genuinely strong, and reading the studies is more grounding than reading another founder’s testimonial.
• If a full-dose experience is calling you, take the retreat option seriously rather than improvising it alone. Set and setting are not buzzwords; they’re most of the experience.

For readers who want to take this further, a range of curated psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, decide it slowly. These are old medicines moving through a very new world, and the people who get the most out of them tend to be the ones who took their time getting in.